胰岛素剂量与死亡率或主要不良心血管事件的关联:一项回顾性队列研究
基于英国临床实践研究数据链的回顾性队列研究,纳入6072例新加用胰岛素的2型糖尿病患者,按日均胰岛素剂量分组。常规多变量Cox模型显示较高胰岛素剂量与死亡率升高相关,但应用边际结构模型后胰岛素剂量与死亡率无关联,提示该关联可能受时间依赖混杂因素影响。
要点
- 常规多变量模型下,较高胰岛素剂量与死亡率升高相关。
- 边际结构模型校正后,胰岛素剂量与死亡率无关联。
- 作者认为该效应可能受胰岛素暴露、血糖控制、体重增加等因素混杂。
核心结论
- 常规多变量回归分析中,较高胰岛素剂量与死亡率升高相关,但该效应似乎受时间依赖因素混杂。
- 本研究为胰岛素治疗2型糖尿病的总体安全性提供了 reassurance,并有助于理解非随机研究与随机研究关于胰岛素剂量依赖性心血管效应和死亡率结论的差异。
研究设计与样本
- 回顾性队列研究,使用英国临床实践研究数据链(CPRD)初级保健记录,纳入2001年1月1日至2012年12月31日期间新使用二甲双胍单药治疗后新处方胰岛素的2型糖尿病成人。
- 排除标准应用后,6072例新加用胰岛素使用者纳入研究队列(平均年龄60岁[SD 12.5],男性3281例[54%],平均HbA1c 8.5%[SD 1.75],中位随访3.1年[IQR 1.7-5.3]);其中3599例新加用胰岛素使用者纳入与医院记录和死亡证明信息链接的亚队列。
- 胰岛素暴露按每位患者随访期间180天时间段内的日均剂量(单位)分组。
主要发现
- 粗死亡率在各胰岛素剂量组间相当:<25单位/天组46例/1000人年,25至<50单位/天组39例/1000人年,50至<75单位/天组27例/1000人年,75至<100单位/天组34例/1000人年,至少100单位/天组32例/1000人年(所有p>0.05;平均死亡率31例死亡/1000人年[95%CI 29-33])。
- 校正基线协变量后,死亡率随胰岛素剂量增加而升高:<25单位/天组为参照组;25至<50单位/天组HR 1.41[95%CI 1.12-1.78];50至<75单位/天组HR 1.37[95%CI 1.04-1.80];75至<100单位/天组HR 1.85[95%CI 1.35-2.53];至少100单位/天组HR 2.16[95%CI 1.58-2.93]。
- 应用边际结构模型后,任何胰岛素剂量组与死亡率均无关联(所有p>0.1)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Existing studies have shown conflicting evidence regarding the safety of exogenous insulin therapy in patients with type 2 diabetes. In particular, observational studies have reported an increased risk of death and cardiovascular disease among users of higher versus lower doses of insulin. We aimed to quantify the association between increasing dosage of insulin exposure and death and cardiovascular events, while taking into account time-dependent confounding and mediation that might have biased previous studies. METHODS: We did a cohort study using primary care records from the UK-based Clinical Practice Research Datalink (CPRD). New users of metformin monotherapy were identified in the period between Jan 1, 2001, and Dec 31, 2012. We then identified those in this group with a new prescription for insulin. Insulin exposure was categorised into groups according to the mean dose (units) per day within 180-day time segments throughout each patient's follow-up. Relative differences in mortality and major adverse cardiovascular events (non-fatal myocardial infarction, non-fatal stroke, cardiovascular-related mortality) were assessed using conventional multivariable Cox proportional hazards models. Marginal structural models were then applied to reduce bias introduced by the time-dependent confounders affected by previous treatment. FINDINGS: We identified 165 308 adults with type 2 diabetes in the CPRD database. After applying our exclusion criteria, 6072 (mean age 60 years [SD 12·5], 3281 [54%] men, mean HbA1c 8·5% [SD 1·75], and median follow-up 3·1 years [IQR 1·7-5·3) were new add-on insulin users and were included in the study cohort; 3599 were new add-on insulin users and were included in the subcohort linked to hospital records and death certificate information. Crude mortality rates were comparable between insulin dose groups; <25 units per day (46 per 1000 person-years), 25 to <50 units per day (39 per 1000 person-years), 50 to <75 units per day (27 per 1000 person-years), 75 to <100 units per day (34 per 1000 person-years), and at least 100 units per day (32 per 1000 person-years; p>0·05 for all; mean rate of 31 deaths per 1000 person-years [95% CI 29-33]). With adjustment for baseline covariates, mortality rates were higher for increasing insulin doses: less than 25 units per day [reference group]; 25 to <50 units per day, hazard ratio (HR) 1·41 [95% CI 1·12-1·78]; 50 to <75 units per day, 1·37 [1·04-1·80]; 75 to <100 units per day, 1·85 [1·35-2·53]; and at least 100 units per day, 2·16 [1·58-2·93]. After applying marginal structural models, insulin dose was not associated with mortality in any group (p>0·1 for all). INTERPRETATION: In conventional multivariable regression analysis, higher insulin doses are associated with increased mortality after adjustment for baseline covariates. However, this effect seems to be confounded by time-dependent factors such as insulin exposure, glycaemic control, bodyweight gain, and the occurrence of cardiovascular and hypoglycaemic events. This study provides reassurance of the overall safety of insulin use in the treatment of type 2 diabetes and contributes to our understanding of the contrasting conclusions from non-randomised and randomised studies regarding dose-dependent effects of insulin on cardiovascular events and mortality. FUNDING: Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, and the Newfoundland and Labrador Research and Development Corporation.
引用
- Gamble JM, Chibrikov E, Twells LK, et al. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol. 2016. PMID: 27865756. doi:10.1016/S2213-8587(16)30316-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。